Dopamine-noradrenaline reuptake inhibitor
Solriamfetol
Brand names: Sunosi
Adult dose
Dose: Initial 75mg PO OM, may double after 3 days; max 150mg/day
Route: PO
Frequency: OM
Clinical pearls
- Excessive daytime sleepiness in narcolepsy or OSA
- Monitor BP — can raise BP and HR
Contraindications
- Concurrent MAOI / within 14 days
- Hypersensitivity
Side effects
- Headache
- Nausea
- Insomnia
- Hypertension
- Increased HR
- Anxiety
Interactions
- MAOIs
- Sympathomimetics
- Dopaminergic drugs
Monitoring
- BP
- HR
Reference: BNF; NICE TA758; SmPC; https://bnf.nice.org.uk/drugs/solriamfetol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS